<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838162</url>
  </required_header>
  <id_info>
    <org_study_id>CR015952</org_study_id>
    <secondary_id>TMC310911-TIDP21-C201</secondary_id>
    <secondary_id>2008-008190-58</secondary_id>
    <nct_id>NCT00838162</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients</brief_title>
  <official_title>A Phase IIa, Open-label, Randomized Trial in Treatment-naive HIV-1-infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 4 Different Dose Regimens of TMC310911 Coadministered With Ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral activity as measured by the change in
      viral load from baseline in the 14 days following initiation of treatment with 4 different
      dose regimens of TMC310911 co-administered with ritonavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention) and randomized
      (study medication assigned by chance) study in treatment-naive human immunodeficiency virus
      type 1 (HIV-1)-infected participants (participants who had not been treated with a
      therapeutic HIV vaccine within 1 year prior to enrollment and who had never been treated with
      an antiretroviral [ARV] medication indicated for the treatment of HIV-infection or ARVs for
      treatment of hepatitis B infection with anti-HIV activity prior to screening). In this study
      approximately 32 participants will be enrolled and randomly assigned to receive 4 different
      dose regimens co-administered with ritonavir (8 participants in each dosing regimen). The
      trial will consist of a screening period (maximum 6 weeks), a treatment period with TMC310911
      (2 weeks), and a follow-up period (4 weeks). Safety evaluation will include assessment of
      adverse events, clinical laboratory tests, vital sign measurements, physical examinations and
      electrocardiograms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA)</measure>
    <time_frame>Baseline (Day 1), Day 8, Day 15</time_frame>
    <description>The antiviral activity of TMC310911 is measured by the change in viral load from baseline in the 14 days of treatment following initiation of treatment with 4 different dosing regimens of TMC310911 coadministered with ritonavir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virologic Response at Any Timepoint During the 14-day Treatment Period</measure>
    <time_frame>14 days</time_frame>
    <description>Virologic response is a viral load test result below a chosen threshold value (less than 50 copies/mL, less than 400 copies/mL, or at least 1 log drop in viral load) at any timepoint during a 14-day treatment of 4 different dose regimens of TMC310911 coadministered with 100 mg ritonavir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes From Baseline in CD4+ Cell Count</measure>
    <time_frame>Baseline (Day 1), Day 8, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of TMC310911</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC310911</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC12) From the Time of Administration of TMC310911 up to 12 Hours After Dosing</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Plasma Concentration (C0h) of TMC310911</measure>
    <time_frame>Day 2, Day 3, Day 4, Day 6, Day 8, Day 10, Day 12 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Steady-state Plasma Concentration (Css,av) of TMC310911</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation Index of TMC310911</measure>
    <time_frame>Day 14</time_frame>
    <description>Fluctuation index, ie, percentage fluctuation: variation between maximum (Cmax) and minimum (Cmin) plasma concentration at steady-state, calculated as: 100 x ([Cmax-Cmin]/Css,av). Css,av is an average steady-state plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Human Immunodeficiency Virus Type 1</condition>
  <arm_group>
    <arm_group_label>TMC310911/rtv 75/100 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC310911/rtv 150/100 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC310911/rtv 300/100 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC310911/rtv 300/100 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC310911 75 mg twice daily</intervention_name>
    <description>TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.</description>
    <arm_group_label>TMC310911/rtv 75/100 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC310911 150 mg twice daily</intervention_name>
    <description>TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14</description>
    <arm_group_label>TMC310911/rtv 150/100 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC310911 300 mg twice daily</intervention_name>
    <description>TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14</description>
    <arm_group_label>TMC310911/rtv 300/100 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC310911 300 mg once daily</intervention_name>
    <description>TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14</description>
    <arm_group_label>TMC310911/rtv 300/100 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg twice daily</intervention_name>
    <description>Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14</description>
    <arm_group_label>TMC310911/rtv 75/100 mg twice daily</arm_group_label>
    <arm_group_label>TMC310911/rtv 150/100 mg twice daily</arm_group_label>
    <arm_group_label>TMC310911/rtv 300/100 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg once daily</intervention_name>
    <description>Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14</description>
    <arm_group_label>TMC310911/rtv 300/100 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months
             prior to the screening date

          -  Participant who has not been treated with a therapeutic HIV vaccine within 1 year
             prior to enrolment and has never been treated with an antiretroviral (ARV) medication
             indicated for the treatment of HIV infection or ARVs for treatment of hepatitis
             B-infection with anti-HIV activity

          -  Participant agrees not to start antiretroviral therapy (ART) before the baseline visit

          -  Able to comply with the protocol requirements and have good accessible veins

          -  HIV-1 plasma viral load at screening visit of above 5,000 HIV-1 Ribonucleic acid
             copies/mL

          -  CD4+ cell count above 200 cells/mm3 at screening

        Exclusion Criteria:

          -  HIV-2 infected participants and/or participants with any active or chronic
             hepato-renal disease

          -  Life expectancy of less than 6 months

          -  Documented acute (primary) HIV-1 infection

          -  Pre-existing protease inhibitor (PI) medication resistance

          -  Any currently active Acquired Immunodeficiency Syndrome (AIDS) - defining illness

          -  Any active clinically significant disease or findings during screening or medical
             history or physical examination that in the investigator's opinion, would compromise
             the outcome of the study

          -  Any confirmed grade 3 or 4 toxicity according to the Division of AIDS (DAIDS) grading
             scale at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals, Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceuticals, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <results_first_submitted>January 30, 2013</results_first_submitted>
  <results_first_submitted_qc>January 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2013</results_first_posted>
  <disposition_first_submitted>July 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human immunodeficiency virus type 1</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV-1 treatment-naive</keyword>
  <keyword>TMC310911</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Antiviral Activity</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in Germany.</recruitment_details>
      <pre_assignment_details>In total, 41 participants were screened of whom 33 participants were randomized and treated with TMC310911. All treated participants completed the study; there were no dropouts or discontinuations during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
          <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="P2">
          <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
          <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="P3">
          <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
          <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="P4">
          <title>TMC310911/Rtv 300/100 mg Once a Day</title>
          <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
          <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="B2">
          <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
          <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="B3">
          <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
          <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="B4">
          <title>TMC310911/Rtv 300/100 mg Once a Day</title>
          <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="7.23"/>
                    <measurement group_id="B2" value="38.1" spread="8.66"/>
                    <measurement group_id="B3" value="35.5" spread="6.87"/>
                    <measurement group_id="B4" value="37.8" spread="10.19"/>
                    <measurement group_id="B5" value="35.1" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA)</title>
        <description>The antiviral activity of TMC310911 is measured by the change in viral load from baseline in the 14 days of treatment following initiation of treatment with 4 different dosing regimens of TMC310911 coadministered with ritonavir.</description>
        <time_frame>Baseline (Day 1), Day 8, Day 15</time_frame>
        <population>Intent-to treat (ITT) population- participants who received at least 1 dose of study medication (TMC310911).</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA)</title>
          <description>The antiviral activity of TMC310911 is measured by the change in viral load from baseline in the 14 days of treatment following initiation of treatment with 4 different dosing regimens of TMC310911 coadministered with ritonavir.</description>
          <population>Intent-to treat (ITT) population- participants who received at least 1 dose of study medication (TMC310911).</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.245"/>
                    <measurement group_id="O2" value="4.36" spread="0.259"/>
                    <measurement group_id="O3" value="4.78" spread="0.161"/>
                    <measurement group_id="O4" value="4.71" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.126"/>
                    <measurement group_id="O2" value="-1.14" spread="0.147"/>
                    <measurement group_id="O3" value="-1.07" spread="0.104"/>
                    <measurement group_id="O4" value="-1.06" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="0.117"/>
                    <measurement group_id="O2" value="-1.79" spread="0.192"/>
                    <measurement group_id="O3" value="-1.69" spread="0.103"/>
                    <measurement group_id="O4" value="-1.55" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virologic Response at Any Timepoint During the 14-day Treatment Period</title>
        <description>Virologic response is a viral load test result below a chosen threshold value (less than 50 copies/mL, less than 400 copies/mL, or at least 1 log drop in viral load) at any timepoint during a 14-day treatment of 4 different dose regimens of TMC310911 coadministered with 100 mg ritonavir.</description>
        <time_frame>14 days</time_frame>
        <population>Intent-to-treat (ITT) Population- all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Response at Any Timepoint During the 14-day Treatment Period</title>
          <description>Virologic response is a viral load test result below a chosen threshold value (less than 50 copies/mL, less than 400 copies/mL, or at least 1 log drop in viral load) at any timepoint during a 14-day treatment of 4 different dose regimens of TMC310911 coadministered with 100 mg ritonavir.</description>
          <population>Intent-to-treat (ITT) Population- all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viral load less than 50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral load less than 400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 log10 Viral Load Drop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes From Baseline in CD4+ Cell Count</title>
        <time_frame>Baseline (Day 1), Day 8, Day 15</time_frame>
        <population>Intent-to-treat (ITT) Population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline in CD4+ Cell Count</title>
          <population>Intent-to-treat (ITT) Population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>x 1000000 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="575.7" spread="56.97"/>
                    <measurement group_id="O2" value="464.9" spread="61.32"/>
                    <measurement group_id="O3" value="494.0" spread="70.43"/>
                    <measurement group_id="O4" value="479.6" spread="39.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="41.23"/>
                    <measurement group_id="O2" value="40.3" spread="45.19"/>
                    <measurement group_id="O3" value="-14.8" spread="47.59"/>
                    <measurement group_id="O4" value="17.9" spread="48.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.7" spread="27.04"/>
                    <measurement group_id="O2" value="-2.8" spread="31.44"/>
                    <measurement group_id="O3" value="-2.0" spread="41.23"/>
                    <measurement group_id="O4" value="92.5" spread="58.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of TMC310911</title>
        <time_frame>Day 1 and Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of TMC310911</title>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.9" spread="450.3"/>
                    <measurement group_id="O2" value="623.0" spread="358.1"/>
                    <measurement group_id="O3" value="706.3" spread="553.2"/>
                    <measurement group_id="O4" value="1924" spread="1048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589.7" spread="554.1"/>
                    <measurement group_id="O2" value="1674" spread="652.3"/>
                    <measurement group_id="O3" value="2256" spread="961.9"/>
                    <measurement group_id="O4" value="2963" spread="1920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC310911</title>
        <time_frame>Day 1 and Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC310911</title>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="3.00" upper_limit="8.12"/>
                    <measurement group_id="O3" value="5.06" lower_limit="5.00" upper_limit="12.17"/>
                    <measurement group_id="O4" value="5.00" lower_limit="2.00" upper_limit="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="5.03"/>
                    <measurement group_id="O3" value="3.87" lower_limit="0.00" upper_limit="5.02"/>
                    <measurement group_id="O4" value="3.02" lower_limit="1.02" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC12) From the Time of Administration of TMC310911 up to 12 Hours After Dosing</title>
        <time_frame>Day 1 and Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC12) From the Time of Administration of TMC310911 up to 12 Hours After Dosing</title>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2519" spread="2123"/>
                    <measurement group_id="O2" value="2735" spread="1572"/>
                    <measurement group_id="O3" value="2990" spread="2245"/>
                    <measurement group_id="O4" value="10040" spread="6122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4031" spread="3845"/>
                    <measurement group_id="O2" value="10680" spread="3147"/>
                    <measurement group_id="O3" value="16010" spread="8229"/>
                    <measurement group_id="O4" value="17520" spread="11610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose Plasma Concentration (C0h) of TMC310911</title>
        <time_frame>Day 2, Day 3, Day 4, Day 6, Day 8, Day 10, Day 12 and Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911).</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Predose Plasma Concentration (C0h) of TMC310911</title>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.95" spread="104.1"/>
                    <measurement group_id="O2" value="207.7" spread="122.9"/>
                    <measurement group_id="O3" value="231.9" spread="199.9"/>
                    <measurement group_id="O4" value="45.48" spread="28.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.98" spread="92.90"/>
                    <measurement group_id="O2" value="448.0" spread="266.1"/>
                    <measurement group_id="O3" value="586.3" spread="454.2"/>
                    <measurement group_id="O4" value="125.9" spread="69.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.94" spread="113.6"/>
                    <measurement group_id="O2" value="291.3" spread="170.2"/>
                    <measurement group_id="O3" value="1035" spread="552.2"/>
                    <measurement group_id="O4" value="191.0" spread="175.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.1" spread="182.1"/>
                    <measurement group_id="O2" value="443.0" spread="284.7"/>
                    <measurement group_id="O3" value="960.5" spread="506.9"/>
                    <measurement group_id="O4" value="250.0" spread="236.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.5" spread="179.0"/>
                    <measurement group_id="O2" value="665.9" spread="461.1"/>
                    <measurement group_id="O3" value="1028" spread="724.1"/>
                    <measurement group_id="O4" value="239.6" spread="242.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.51" spread="57.88"/>
                    <measurement group_id="O2" value="394.4" spread="134.4"/>
                    <measurement group_id="O3" value="736.1" spread="435.0"/>
                    <measurement group_id="O4" value="251.7" spread="211.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.6" spread="82.91"/>
                    <measurement group_id="O2" value="518.6" spread="288.7"/>
                    <measurement group_id="O3" value="1110" spread="547.5"/>
                    <measurement group_id="O4" value="250.2" spread="181.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.5" spread="248.2"/>
                    <measurement group_id="O2" value="420.9" spread="244.6"/>
                    <measurement group_id="O3" value="924.8" spread="527.9"/>
                    <measurement group_id="O4" value="209.9" spread="187.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Steady-state Plasma Concentration (Css,av) of TMC310911</title>
        <time_frame>Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911).</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Average Steady-state Plasma Concentration (Css,av) of TMC310911</title>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.2" spread="321.3"/>
                    <measurement group_id="O2" value="889.6" spread="262.6"/>
                    <measurement group_id="O3" value="1340" spread="689.6"/>
                    <measurement group_id="O4" value="887.3" spread="567.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluctuation Index of TMC310911</title>
        <description>Fluctuation index, ie, percentage fluctuation: variation between maximum (Cmax) and minimum (Cmin) plasma concentration at steady-state, calculated as: 100 x ([Cmax-Cmin]/Css,av). Css,av is an average steady-state plasma concentration.</description>
        <time_frame>Day 14</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
        <group_list>
          <group group_id="O1">
            <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
            <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O2">
            <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
            <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O3">
            <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
            <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
          </group>
          <group group_id="O4">
            <title>TMC310911/Rtv 300/100 mg Once a Day</title>
            <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
          </group>
        </group_list>
        <measure>
          <title>Fluctuation Index of TMC310911</title>
          <description>Fluctuation index, ie, percentage fluctuation: variation between maximum (Cmax) and minimum (Cmin) plasma concentration at steady-state, calculated as: 100 x ([Cmax-Cmin]/Css,av). Css,av is an average steady-state plasma concentration.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC310911)</population>
          <units>Percent ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.0" spread="80.00"/>
                    <measurement group_id="O2" value="161.3" spread="29.22"/>
                    <measurement group_id="O3" value="129.2" spread="52.89"/>
                    <measurement group_id="O4" value="331.8" spread="55.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 weeks after the last dose administration of study medication</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TMC310911/Rtv 75/100 mg Twice Daily</title>
          <description>TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="E2">
          <title>TMC310911/Rtv 150/100 mg Twice Daily</title>
          <description>TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="E3">
          <title>TMC310911/Rtv 300/100 mg Twice Daily</title>
          <description>TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14</description>
        </group>
        <group group_id="E4">
          <title>TMC310911/Rtv 300/100 mg Once a Day</title>
          <description>TMC310911 300 mg + ritonavir 100 mg once a day on Days 1 to 14</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Head of Discovery &amp; Early Development</name_or_title>
      <organization>Jan-Cil UK</organization>
      <phone>44 1494 553458</phone>
      <email>ksimmen1@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

